MedEx answers any queries you might have regarding Zykadia-150 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Description of Zykadia is based on the drug instructions, feedbacks of the patients and the results of clinical studies.
The drug belongs to the latest developments in the treatment of lung cancer. The active substance of Zykadia is a kinase inhibitors and prevents the growth of tumors. Blocking the mutagenic protein in the cell structure detains and stops the growth of tumors.
Zykadia has recommended itself as a good drug for neglected diseases. Its active component improves the general condition, hinders the growth of cancer cells and extends the patient’s life.
Composition and form of production.
Zykadia comes in the form of capsules. Each capsule includes 150 mg of Ceritinib and auxiliary substances.
The drug action is based on the active substance of Ceritinib that (after entering the body) interacts with mutagenic proteins, located in the cancer cells and destroys them. Thus, the drug creates a protective barrier between the mutated area and the health tissue. Ceritinib prevents the misfolded proteins from entering the bloodstream and spreading across the body.
Investigations of drug action were carried out at 163 patients with non-small cell lung cancer. At the end of treatment, 50 patients demonstrated tumor regression. The effect lasted 7 months.
After the intake of Zykadia, the body accumulates its active substance and achieves maximum in 4-6 hours. However, the therapeutic effect increases, and the side effects decrease if you take the drug 2 hours after the meal. The half-life or the drug is 41 hours.
Zykadia is developed for the treatment of non-small cell lung cancer with a kinase-positive anaplastic lymphoma, when the other methods prove ineffective. Positive effect was confirmed by a number of tests on the living patients.
Patients under the age of 18;
Pregnancy or conception. You should refrain from the latter until the end of treatment with Zykadia;
Breastfeeding. The drug can get into the breast milk and harm the baby. If you have to get treatment during lactation, you should use artificial feeding and use the services of the wet nurse;
Different allergic reactions and negative side effects resulted from the intolerance to the drug components;
During the treatment, the patients must not drink grapefruit juice or eat grapefruits not to increase the amount of active substance in the body.
Compatibility with the other medications.
It is not recommended to mix Ceritinib with powerful inhibitors and certain antibiotics (for example, telithromycin, nefazodone, imizadole and antiviral drugs.
Moreover, Ceritinib is incompatible with pimozide, alfentanil, tacrolimus, quinidine and ergotamine; therefore, you should combine it with the other drugs. It is not recommended to mix Ceritinib with powerful inductors: rifampicine, phenytoin, St. John’s wort and carbamazepine.